High-dose statin therapy in patients with stable coronary artery disease : treating the right patients based on individualized prediction of treatment effect
BACKGROUND: Clinicians need to identify coronary artery disease patients for whom the benefits of high-dose versus usual-dose statin therapy outweigh potential harm. We therefore aimed to develop and validate a model for prediction of the incremental treatment effect of high-dose statins for individual patients in terms of reduction of 5-year absolute risk for myocardial infarction, stroke, coronary death, or cardiac resuscitation.
METHODS AND RESULTS: Based on data from the Treating to New Targets trial (TNT; n=10 001), a Cox proportional hazards model was developed comprising 13 easy-to-measure clinical predictors: age, sex, smoking, diabetes mellitus, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, history of myocardial infarction, coronary artery bypass grafting, congestive heart failure or abdominal aortic aneurysm, glomerular filtration rate, and treatment status (ie, atorvastatin 80 mg or 10 mg). External validation in the Incremental Decrease in End Points Through Aggressive Lipid Lowering trial (IDEAL; n=8888) confirmed adequate goodness-of-fit and calibration, but moderate discrimination (C-statistic, 0.63; 95% confidence interval, 0.62-0.65). Still, among participants of both trials combined, the model identified a group of 11.7% whose predicted 5-year number needed to treat was ≤25 and a group of 41.9% whose predicted needed to treat was ≥50. A decision curve shows that making treatment decisions on the basis of predictions using our model may improve net benefit.
CONCLUSIONS: Estimation of the incremental treatment effect of high-dose versus usual-dose statin therapy in individual coronary artery disease patients enables selection of high-risk patients that benefit most from more aggressive therapy.
CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00327691 and NCT00159835.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:127 |
|---|---|
| Enthalten in: |
Circulation - 127(2013), 25 vom: 25. Juni, Seite 2485-93 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dorresteijn, Johannes A N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coronary disease |
|---|
| Anmerkungen: |
Date Completed 25.09.2013 Date Revised 10.12.2019 published: Print-Electronic ClinicalTrials.gov: NCT00159835, NCT00327691 Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCULATIONAHA.112.000712 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM227500334 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM227500334 | ||
| 003 | DE-627 | ||
| 005 | 20231224073837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCULATIONAHA.112.000712 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0758.xml |
| 035 | |a (DE-627)NLM227500334 | ||
| 035 | |a (NLM)23674398 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dorresteijn, Johannes A N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High-dose statin therapy in patients with stable coronary artery disease |b treating the right patients based on individualized prediction of treatment effect |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.09.2013 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT00159835, NCT00327691 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Clinicians need to identify coronary artery disease patients for whom the benefits of high-dose versus usual-dose statin therapy outweigh potential harm. We therefore aimed to develop and validate a model for prediction of the incremental treatment effect of high-dose statins for individual patients in terms of reduction of 5-year absolute risk for myocardial infarction, stroke, coronary death, or cardiac resuscitation | ||
| 520 | |a METHODS AND RESULTS: Based on data from the Treating to New Targets trial (TNT; n=10 001), a Cox proportional hazards model was developed comprising 13 easy-to-measure clinical predictors: age, sex, smoking, diabetes mellitus, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, history of myocardial infarction, coronary artery bypass grafting, congestive heart failure or abdominal aortic aneurysm, glomerular filtration rate, and treatment status (ie, atorvastatin 80 mg or 10 mg). External validation in the Incremental Decrease in End Points Through Aggressive Lipid Lowering trial (IDEAL; n=8888) confirmed adequate goodness-of-fit and calibration, but moderate discrimination (C-statistic, 0.63; 95% confidence interval, 0.62-0.65). Still, among participants of both trials combined, the model identified a group of 11.7% whose predicted 5-year number needed to treat was ≤25 and a group of 41.9% whose predicted needed to treat was ≥50. A decision curve shows that making treatment decisions on the basis of predictions using our model may improve net benefit | ||
| 520 | |a CONCLUSIONS: Estimation of the incremental treatment effect of high-dose versus usual-dose statin therapy in individual coronary artery disease patients enables selection of high-risk patients that benefit most from more aggressive therapy | ||
| 520 | |a CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00327691 and NCT00159835 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Validation Study | |
| 650 | 4 | |a coronary disease | |
| 650 | 4 | |a forecasting | |
| 650 | 4 | |a prevention & control | |
| 650 | 4 | |a statins, HMG-CoA | |
| 650 | 4 | |a treatment outcome | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Boekholdt, S Matthijs |e verfasserin |4 aut | |
| 700 | 1 | |a van der Graaf, Yolanda |e verfasserin |4 aut | |
| 700 | 1 | |a Kastelein, John J P |e verfasserin |4 aut | |
| 700 | 1 | |a LaRosa, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Pedersen, Terje R |e verfasserin |4 aut | |
| 700 | 1 | |a DeMicco, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Ridker, Paul M |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Nancy R |e verfasserin |4 aut | |
| 700 | 1 | |a Visseren, Frank L J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation |d 1950 |g 127(2013), 25 vom: 25. Juni, Seite 2485-93 |w (DE-627)NLM000039020 |x 1524-4539 |7 nnns |
| 773 | 1 | 8 | |g volume:127 |g year:2013 |g number:25 |g day:25 |g month:06 |g pages:2485-93 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCULATIONAHA.112.000712 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 127 |j 2013 |e 25 |b 25 |c 06 |h 2485-93 | ||